share_log

StockNews.com Initiates Coverage on Acorda Therapeutics (NASDAQ:ACOR)

kopsource ·  Sep 28, 2022 02:02

Equities researchers at StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a report released on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.

Acorda Therapeutics Price Performance

Shares of ACOR stock opened at $0.29 on Monday. The company has a market cap of $7.06 million, a P/E ratio of -0.03 and a beta of 0.45. The company has a quick ratio of 1.49, a current ratio of 1.86 and a debt-to-equity ratio of 2.10. The business has a fifty day simple moving average of $0.42 and a 200 day simple moving average of $0.77. Acorda Therapeutics has a twelve month low of $0.28 and a twelve month high of $4.94.

Get Acorda Therapeutics alerts:

Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($2.42). Acorda Therapeutics had a negative return on equity of 90.29% and a negative net margin of 98.25%. The firm had revenue of $31.05 million for the quarter.

Institutional Trading of Acorda Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Prudential Financial Inc. bought a new position in shares of Acorda Therapeutics during the 2nd quarter valued at $28,000. Virtu Financial LLC purchased a new position in Acorda Therapeutics during the second quarter valued at $68,000. Millennium Management LLC grew its holdings in Acorda Therapeutics by 661.2% in the second quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock worth $145,000 after purchasing an additional 270,588 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Acorda Therapeutics by 27.4% during the second quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after buying an additional 194,100 shares during the last quarter. Hedge funds and other institutional investors own 50.24% of the company's stock.

About Acorda Therapeutics

(Get Rating)

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.

Further Reading

  • Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
  • Defensive Stocks For A Volatile Market
  • SunPower Is Ready To Power Up Triple-Digit Earnings Gains
  • Will UPS Be Next to Deliver a Warning?
  • Is This the Darkest Before the Dawn for Gap Stock?
  • Build A Better Tech Portfolio With Jabil Inc.

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment